Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
Pharmaceutical interventions play a vital role in managing various conditions, including weight-related issues such as obesity. In this context, lifestyle changes are often challenging to maintain, especially for individuals struggling with this condition. Obesity is strongly linked to serious healt...
Saved in:
Main Authors: | Alexander C. Martins, Beatriz G. de la Torre, Fernando Albericio |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration
2024-04-01
|
Series: | Exploration of Drug Science |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100839/100839.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01) -
The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01) -
The role of glucagon-like peptide-1 receptor (GLP-1R) agonists in enhancing endothelial function: a potential avenue for improving heart failure with preserved ejection fraction (HFpEF)
by: Darshan Hullon, et al.
Published: (2025-02-01) -
Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01) -
Nature-inspired and medicinally relevant short peptides
by: Maria G. Ciulla, et al.
Published: (2023-06-01)